Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1020

1.

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.

Yaghi S, Kamel H, Elkind MS.

Neurology. 2015 Jul 17. pii: 10.1212/WNL.0000000000001817. [Epub ahead of print] Review.

PMID:
26187229
2.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Guégan M, Bosson JL, Laporte S, Leroyer C, Décousus H, Meyer G, Mottier D; PADIS-PE Investigators.

JAMA. 2015 Jul 7;314(1):31-40. doi: 10.1001/jama.2015.7046.

PMID:
26151264
3.

The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.

Gonda DD, Fridley J, Ryan SL, Briceño V, Lam SK, Mba MD, Luerssen TG, Jea A.

J Neurosurg Pediatr. 2015 Jun 12:1-6. [Epub ahead of print]

PMID:
26067336
4.

Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.

Gehrie E, Tormey C.

Arch Pathol Lab Med. 2015 May;139(5):687-92. doi: 10.5858/arpa.2013-0677-RS. Review.

PMID:
25927153
5.

Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.

Messerschmidt C, Friedman RJ.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):771-8. doi: 10.1161/ATVBAHA.114.303400. Epub 2015 Mar 12. Review.

PMID:
25767271
6.

Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.

Shields AM, Lip GY.

J Intern Med. 2015 Jul;278(1):1-18. doi: 10.1111/joim.12360. Epub 2015 Apr 15.

PMID:
25758241
7.

Cost effectiveness of continued-warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery.

Coyle D, Coyle K, Essebag V, Birnie DH, Ahmad K, Toal S, Sapp J, Healey JS, Verma A, Wells G, Krahn AD.

J Am Coll Cardiol. 2015 Mar 10;65(9):957-9. doi: 10.1016/j.jacc.2014.11.060. No abstract available.

PMID:
25744016
8.

[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].

Oberhofer E.

MMW Fortschr Med. 2015 Jan 19;157(1):24. German. No abstract available.

PMID:
25743289
9.

[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].

Sukovatykh BS, Belikov LN, Savchuk OF, Sukovatykh MB.

Vestn Khir Im I I Grek. 2014;173(4):87-91. Russian.

PMID:
25552114
10.

Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.

Pathak R, Pandit A, Karmacharya P, Aryal MR, Ghimire S, Poudel DR, Shamoun FE.

Am J Cardiol. 2015 Feb 1;115(3):323-7. doi: 10.1016/j.amjcard.2014.10.042. Epub 2014 Nov 13.

PMID:
25527282
11.

The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.

Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA.

Am J Gastroenterol. 2015 Feb;110(2):328-35. doi: 10.1038/ajg.2014.398. Epub 2014 Dec 16. Erratum in: Am J Gastroenterol. 2015 Mar;110(3):480.

PMID:
25512338
12.

In catheter ablation of AF, continuing vs interrupting warfarin reduced periprocedural thromboembolic events.

Homoud MK.

Ann Intern Med. 2014 Dec 16;161(12):JC12. doi: 10.7326/0003-4819-161-12-201412160-02012. No abstract available.

PMID:
25506872
13.

Treatment patterns and outcomes among hospitalized patients with venous thromboembolism in the United States: an analysis of electronic health records data.

Menzin J, Preblick R, Friedman M, Menzin J, Frean M, Jacqueline Kwong W.

Hosp Pract (1995). 2014 Oct;42(4):59-74. doi: 10.3810/hp.2014.10.1143.

PMID:
25502130
14.

Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.

Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB.

J Am Coll Cardiol. 2014 Dec 16;64(23):2471-82. doi: 10.1016/j.jacc.2014.09.051.

PMID:
25500231
15.

Parenteral anticoagulation in ambulatory patients with cancer.

Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, Middeldorp S, Bryant A, Schünemann H.

Cochrane Database Syst Rev. 2014 Dec 10;12:CD006652. doi: 10.1002/14651858.CD006652.pub4. Review.

PMID:
25491949
16.

[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].

Beliavskaia OO, Vavilova TV.

Angiol Sosud Khir. 2014;20(4):37-41. Russian.

PMID:
25490355
17.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
18.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.

Lip GY, Wang KL, Chiang CE.

Int J Cardiol. 2015 Feb 1;180:246-54. doi: 10.1016/j.ijcard.2014.11.182. Epub 2014 Nov 26.

PMID:
25463377
19.

Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts).

Ashburner JM, Go AS, Reynolds K, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE.

Am J Cardiol. 2015 Jan 1;115(1):40-6. doi: 10.1016/j.amjcard.2014.10.006. Epub 2014 Oct 12.

PMID:
25456871
20.

Antithrombotic and anticoagulant therapy for atrial fibrillation.

Dzeshka MS, Lip GY.

Cardiol Clin. 2014 Nov;32(4):585-99. doi: 10.1016/j.ccl.2014.07.009. Epub 2014 Sep 2. Review.

PMID:
25443239
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk